default author photo

Youko Suehiro

National Hospital Organization Kyushu Cancer Center - Department of Hematology and Cell Therapy

SCHOLARLY PAPERS

2

DOWNLOADS

99

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Outcomes in Human T-Cell Leukemia Virus Type I Carriers after Hematopoietic Stem Cell Transplantation for Diseases Other than Adult T Cell Leukemia/Lymphoma

Number of pages: 28 Posted: 25 Mar 2023
Imamura General Hospital - Department of Hematology, Jichi Medical University Saitama Medical Center - Division of Hematology, Osaka International Cancer Institute - Department of Hematology, Tokyo Women's Medical University - Department of Hematology, Shimane University Hospital Cancer Center, Imamura General Hospital - Department of Hematology, Hamanomachi Hospital - Department of Hematology, University of the Ryukyus - Second Department of Internal Medicine, Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Hyogo Medical University Hospital - Department of Hematology, Asahikawa City Hospital - Department of Hematology, Okayama University Hospital - Department of Hematology and Oncology, Kyushu University Hospital - Hematology, Oncology & Cardiovascular medicine, National Hospital Organization Kyushu Cancer Center - Department of Hematology and Cell Therapy, Toranomon Hospital - Department of Hematology, National Cancer Center Hospital - Department of Hematopoietic Stem Cell Transplantation, Komagome Hospital - Hematology Division, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital - Department of Hematology, Kyoto University - Department of Hematology and Oncology, Jichi Medical University - Division of Hematology, National Cancer Center Hospital - Department of Hematopoietic Stem Cell Transplantation, Japanese Data Center for Hematopoietic Cell Transplantation and Oita University - Department of Medical Oncology and Hematology
Downloads 78 (816,709)

Abstract:

Loading...

HTLV-1, stem cell transplantation, diseases other than ATL

2.

A First-in-Human Phase 1/2 Dose-Escalation Study of Mak683 (Eed Inhibitor) in Patients with Advanced Malignancies

Number of pages: 21 Posted: 09 Oct 2024
Gustave Roussy - Drug Development Department (DITEP), Instituto de Investigación Sanitaria Hospital "12 de Octubre" - Hospital Universitario 12 de Octubre, affiliation not provided to SSRN, The Chinese University of Hong Kong (CUHK), Shizuoka Cancer Center, University of Cologne, University of Toronto - Princess Margaret Cancer Centre, Sarah Cannon Research Institute, affiliation not provided to SSRN, National Cancer Centre Singapore - Division of Medical Oncology, Humanitas University - Department of Biomedical Sciences, affiliation not provided to SSRN, National Hospital Organization Kyushu Cancer Center - Department of Hematology and Cell Therapy, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 21 (1,448,301)

Abstract:

Loading...

MAK683, EED, PRC2, DLBCL, ES, dose-escalation